<DOC>
	<DOCNO>NCT02361242</DOCNO>
	<brief_summary>PLEODIAL-II study extension previous pilot PLEODIAL-I study ( CLN-PXT00864-03 protocol ) design descriptive analysis patient mild AD expose PXT00864 additional 24-week period .</brief_summary>
	<brief_title>24-week Open-label Extension Study Evaluating PXT00864 Effect Mild AD Patients Further PLEODIAL-I Completion</brief_title>
	<detailed_description>Patients complete previous 12-week PLEODIAL-I study eligible receive PXT00864 24-week open-label extension PLEODIAL-II study order collect additional long-term data regard safety potential effect PXT00864 cognitive behavioural impairment .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Main Mild Alzheimer 's Disease patient include PLEODIALI study Mini Mental State Examination ( MMSE ) score great equal 20 Main Patient compliant previous PLEODIALI study protocol Patient experience significant adverse event necessitate treatment discontinuation PLEODIALI study</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>PXT00864</keyword>
	<keyword>mild AD</keyword>
	<keyword>phase 2a</keyword>
</DOC>